Nanobac Announces European Heart Journal Publication of Association Between Calcifying Nanoparticles and Aortic Stenosis
The authors contend: "For the first time, this study shows that CNP could be causally related to aortic stenosis in humans. We suggest that CNPs colonize the aortic valve, provoking an inflammatory response, resulting in valve calcification via two distinct mechanisms: directly given their capacity to precipitate calcium in the shape of apatite crystals, at physiological calcium and phosphate concentrations, and indirectly by activating the inflammatory pathways."
"Although the finding of nanoparticles in such a significant number of patients with calcific aortic stenosis does not establish that such particles influence this condition, the question of such influence now `begs' to be answered," said Richard A Berger MD.FACC., Asst Professor of Cardiology University of Miami Medical School.
Diagnosis for the presence of CNPs in these patients may be of help in learning more about this frequently fatal disease. Aortic valve stenosis affects 2-8% of adults over the age of 65, and is the number one indication for surgical valve replacement in the US and Europe. Nanobac has developed proprietary diagnostics to identify patients that could benefit from therapy for preventing the advance of this disease to stages needing surgery. Valve replacement surgery is currently the only curative treatment, but it is limited to patients of younger age, better health and has the limitation of the need for anticoagulant therapy not suitable for all patients. Nanobac also has therapies that treat CNPs, and could eliminate the need for surgery.
Nanobac Pharmaceuticals Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.
Nanobac Pharmaceuticals Inc., Tampa
Brady Millican, 813-264-2241
Jens Dalsgaard, 415-884-0348
Posted: January 2008